Storyline
FDA Commissioner Marty Makary, M.D., called J&J’s Tecvayli-Darzalex phase 3 showing the “most impressive second-line myeloma trial results in history.”
J&J's Tecvayli claims third national priority FDA approval Phil.Taylor Fri, 06/03/2026 - 10:59.
Published 2026-03-05 18:23 UTCUpdated 2026-03-06 16:46 UTC
Current brief openSource links open
This current storyline is open here with summary, metadata, source links, continuity context, and full evidence. Paid is for compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
J&J's Tecvayli claims third national priority FDA approval Phil.Taylor Fri, 06/03/2026 - 10:59.
Score total
1.97
Momentum 24h
5
Posts
5
Origins
3
Source types
3
Duplicate ratio
20%
Continuity snapshot
- Trend status: insufficient_history.
- Continuity stage: emerging_confirmed.
- Current status: open.
- 5 current source-linked posts are attached to this storyline.
All evidence
All evidence
FDA issues speedy approval to J&J’s Tecvayli-Darzalex combo
BioPharma Dive · biopharmadive.com · 2026-03-06 16:41 UTC
J&J's Tecvayli-Darzalex multiple myeloma combo takes home FDA's 3rd national priority nod
biotech · fiercepharma.com · 2026-03-06 14:26 UTC
J&J's Tecvayli claims third national priority FDA approval
pharmaphorum · pharmaphorum.com · 2026-03-06 10:59 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 3Origin domains: 3Duplicates: -
Showing 3 / 0
Top publishers (this list)
- BioPharma Dive (1)
- biotech (1)
- pharmaphorum (1)
Top origin domains (this list)
- biopharmadive.com (1)
- fiercepharma.com (1)
- pharmaphorum.com (1)